Viridian Therapeutics, Inc. (0K1R.L) LSE

Currency In USD

AD

Valuation

Market Cap2.64B
Enterprise Value2.48B
P/E Ratio-7.97
PEG Ratio0.43
Price/Sales Ratio133.2
Price/Book Ratio6.03
Enterprise/Revenue135.88
Enterprise/EBITDA-8.22

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterSeptember 30, 2026

Profitability

Profit Margin-17.24
Operating Margin-17.81
AD

Management Effectiveness

Return On Assets-0.44
Return On Equity-0.7

Income Statement

Revenue70.85M
Revenue/Share0.23
Gross Profit69.69M
EBITDA-362.24M
Net Income-342.6M
Diluted EPS-3.32

Balance Sheet

Total Cash956.51M
Total Cash/Share8.42
Total Debt243.27M
Total Debt/Equity0.42
Current Ratio14.46
Book Value Per Share5.12

Price History

52-Week Change8.88
52-Week High34.31
52-Week Low13.25
Moving Average 50 Days22.22
Moving Average 200 Days21.67

Statistics

Average Volume1,574
Shares Outstanding113.56M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:15
Last Split DateSeptember 21, 2021
AD